



## Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.

Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com

### Unaudited [ Provisional ] Consolidated Financial Results for the Quarter ended September 30, 2008.

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [ except for share data ]							Rupees in Lacs [ except for share data ]				
3 Months ended September 30, 2008 [UnAudited]	3 Months ended September 30, 2007 [UnAudited]	Half Year ended September 30, 2008 [UnAudited]	Half Year ended September 30, 2007 [UnAudited]	Previous Accounting Year ended on March 31, 2008 [ Audited ]			3 Months ended September 30, 2008 [UnAudited]	3 Months ended September 30, 2007 [UnAudited]	Half Year ended September 30, 2008 [UnAudited]	Half Year ended September 30, 2007 [UnAudited]	Previous Accounting Year ended on March 31, 2008 [ Audited ]
75860	62138	145638	120687	236380	1	Sales & Income from operations :	48486	44582	92330	91032	171914
2075	2460	3280	4924	9777	A	Gross Sales	1414	2244	2345	4403	7713
73785	59678	142358	115763	226603	B	Less : Excise Duty	47072	42338	89985	86629	164201
308	1287	3141	2417	5845	C	Net Sales	6884	2400	12184	3337	9964
74093	60965	145499	118180	232448	D	Other Income from Operations	53956	44738	102169	89966	174165
					E	Total sales and other income from operations					
					2	Expenditure :					
(6094)	(1468)	(3742)	(787)	(4552)	A	Increase [-] / Decrease [+] in stock in trade & work in progress	(3510)	(281)	(210)	589	330
15195	13386	31787	27916	54060	B	Consumption of materials	14030	11417	22866	24068	45374
14166	8010	18990	13740	29520	C	Purchase of traded goods	5560	4530	10060	8250	17431
9260	7721	18105	13511	27656	D	Employees cost	5933	4759	11824	9300	19254
2590	2353	5048	4739	9687	E	Depreciation & Amortisation	1930	1805	3848	3568	7337
26316	20145	48940	39515	79785	F	Other Expenditure	20079	14093	36773	29689	58568
61433	50147	119128	98634	196156	G	Total Expenditure	44022	36323	85161	75464	148294
12660	10818	26371	19546	36292	3	Profit from Operations before Other Income, Interest & Exceptional Items [ 1 - 2 ]	9934	8415	17008	14502	25871
7	2	34	33	88	4	Other Income	1057	608	2062	1672	3988
12667	10820	26405	19579	36380	5	Profit before Interest & Exceptional Items [ 3 + 4 ]	10991	9023	19070	16174	29859
994	1370	2475	2096	4443	6 A	Interest & financial charges	548	802	1632	1325	3098
1135	(100)	2452	(1010)	(1090)	B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	(147)	(100)	774	(1011)	(1092)
2129	1270	4927	1086	3353	C	Total Financial cost	401	702	2406	314	2006
10538	9550	21478	18493	33027	7	Profit after Interest but before Exceptional Items [ 5 - 6 ]	10590	8321	16664	15860	27853
(182)	(240)	(182)	(240)	(691)	8	Exceptional Items	0	(244)	0	(244)	(484)
10356	9310	21296	18253	32336	9	Profit [+ ] / Loss [-] from Ordinary Activities before tax [ 7 + 8 ]	10590	8077	16664	15616	27369
1008	1135	2241	2348	6126	10	Tax expense	1040	950	1550	1850	3750
9348	8175	19055	15905	26210	11	Net Profit [+ ] / Loss [-] from Ordinary Activities after tax [ 9 - 10 ]	9550	7127	15114	13766	23619
0	0	0	0	0	12	Extraordinary items [ net of tax expense ]	0	0	0	0	0
9348	8175	19055	15905	26210	13	Net Profit [+ ] / Loss [-] for the period [ 11 - 12 ]	9550	7127	15114	13766	23619
140	(164)	(600)	(500)	(451)	14	Adjustments on consolidation	0	0	0	0	0
9488	8011	18455	15405	25759	15	Net Profit [+ ] / Loss [-] for the period [ 13 + 14 ]	9550	7127	15114	13766	23619
6280	6280	6280	6280	6280	16	Paid-up equity share capital [ Face Value Rs. 5 /- ]	6280	6280	6280	6280	6280
					17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year					99100
7.55	6.38	14.69	12.26	20.51	18	Earnings Per Share [ EPS ] [ For the period - not Annualised ]:	7.60	5.67	12.03	10.96	18.80
7.55	6.38	14.69	12.26	20.51	A	Basic and diluted EPS before Extraordinary items [ Rs. ]	7.60	5.67	12.03	10.96	18.80
					B	Basic and diluted EPS after Extraordinary items [ Rs. ]					
					19	Public shareholding :					
						- Number of shares	35150458	35150458	35150458	35150458	35150458
						- Percentage of Shareholding	27.98%	27.98%	27.98%	27.98%	27.98%

#### Notes :

- [ 1 ] Pursuant to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standaloneresults of the company on the company's website: www.zyduscadila.com and/or on the websites of BSE [ www.bseindia.com ] and / or NSE [ www.nseindia.com ].
- [ 2 ] The above results for the quarter / half year ended on September 30, 2008 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on October 22, 2008 and the Statutory Auditors of the Company have carried out a limited review of the financial results of the Company for the quarter / half year ended September 30, 2008.
- [ 3 ] During the quarter, the Company has acquired 100 % shareholding of Laboratories Combi S.L., Spain through its subsidiary, Zydus Netherland BV, the Netherlands. The Company has further acquired 70 % stake in Simayla Pharmaceuticals [ Proprietary ] Limited through its subsidiary, Zydus Healthcare S.A. Proprietary Limited, (South Africa).
- [ 4 ] During the quarter, the Company has set up a Russian subsidiary -- Zydus IntRus Limited through its Ireland subsidiary Company.
- [ 5 ] The Change in investments during the quarter is as under :  
[ A ] Zydus International Pvt. Ltd. [ Additional Investments ] Rs. 12803 Lacs  
[ B ] M/s. Zydus Healthcare [ A partnership firm ] [ Withdrawal of Capital ] Rs. 215 Lacs
- [ 6 ] No effect is given to the Composite Scheme of Arrangement proposed by the Company for restructuring of its Consumer Products business and approved by members of the Company, pending approval of Honourable High Court of Gujarat.
- [ 7 ] The status of investor complaints :  
Pending at the beginning of the quarter - 1, received during the quarter - 28, disposed off during the quarter - 29 - pending at the end of the quarter - NIL.
- [ 8 ] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,  
For Cadila Healthcare Limited,

Pankaj R. Patel  
Chairman & Managing Director

Mumbai, October 22, 2008.